{"success":true,"data":{"pressRelease":{"id":"11816","rtpr_id":"nNFC3gZcl5","ticker":"IBRX","exchange":"NASDAQ","all_tickers":["IBRX"],"title":"IBRX DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of Securities Class Action Deadline on May 26, 2026","author":"Newsfile Corp","published_at":"2026-04-28T20:48:18.274Z","article_body":"Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson\n(https://api.newsfilecorp.com/redirect/WAjqnsMp3b) Encourages Investors Who\nSuffered Losses In ImmunityBio To Contact Him Directly To Discuss Their\nOptions\n\nIf you purchased or acquired securities in ImmunityBio\n(https://api.newsfilecorp.com/redirect/qpg2EUKepK) between January 19, 2026\nand March 24, 2026 and would like to discuss your legal rights, call Faruqi &\nFaruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext.\n1310).\n\n[You may also click here for additional information]\n(https://api.newsfilecorp.com/redirect/nogWRuMqLj)\n\nNew York, New York--(Newsfile Corp. - April 28, 2026) - Faruqi & Faruqi, LLP\n(https://api.newsfilecorp.com/redirect/KL50ASJGqw), a leading national\nsecurities law firm, is investigating potential claims against ImmunityBio,\nInc. (\"ImmunityBio\" or the \"Company\") (NASDAQ: IBRX) and reminds investors of\nthe May 26, 2026 deadline to seek the role of lead plaintiff in a federal\nsecurities class action that has been filed against the Company.\n\n(https://images.newsfilecorp.com/files/6455/294678_3eff907dc4cb4ad8_001full.jpg)\n\nFaruqi & Faruqi is a leading national securities law firm with offices in New\nYork, Pennsylvania, California and Georgia. The firm has recovered hundreds of\nmillions of dollars for investors since its founding in 1995. See\nwww.faruqilaw.com.\n\nAs detailed below, the complaint alleges that the Company and its executives\nviolated federal securities laws by making false and/or misleading statements\nand/or failing to disclose that: (1) Defendant Patrick Soon-Shiong materially\noverstated Anktiva's capabilities; and (2) as a result, defendants' statements\nabout ImmunityBio's business, operations, and prospects were materially false\nand misleading and/or lacked a reasonable basis at all relevant times. When\nthe true details entered the market, the lawsuit claims that investors\nsuffered damages.\n\nOn January 23, 2026, ImmunityBio issued a press release \"announc[ing] updated\nPhase 2 clinical results from QUILT 3.078 (NCT06061809), evaluating a\nchemotherapy-free combination immunotherapy regimen in patients with\nsecond-line recurrent or progressive glioblastoma (GBM), as well as patients\ntreated under single-patient INDs (spINDs) across first- to third-line\ndisease.\" Among other results, the press release disclosed that \"median\noverall survival\"-the primary endpoint for the trial-\"has not yet been\nreached[.]\"\n\nOn this news, ImmunityBio's stock price fell $0.89 per share, or 12.13%, to\nclose at $6.45 per share on January 23, 2026.\n\nThe court-appointed lead plaintiff is the investor with the largest financial\ninterest in the relief sought by the class who is adequate and typical of\nclass members who directs and oversees the litigation on behalf of the\nputative class. Any member of the putative class may move the Court to serve\nas lead plaintiff through counsel of their choice, or may choose to do nothing\nand remain an absent class member. Your ability to share in any recovery is\nnot affected by the decision to serve as a lead plaintiff or not.\n\nFaruqi & Faruqi, LLP also encourages anyone with information regarding\nImmunityBio's conduct to contact the firm, including whistleblowers, former\nemployees, shareholders and others.\n\nTo learn more about the ImmunityBio class action, go to www.faruqilaw.com/IBRX\nor call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or\n212-983-9330 (Ext. 1310).\n\nFollow us for updates on LinkedIn\n(https://api.newsfilecorp.com/redirect/7n5B2uMyKW), on X\n(https://api.newsfilecorp.com/redirect/ejgD7UMAE7), or on Facebook\n(https://api.newsfilecorp.com/redirect/87LE2cOKvk).\n\nAttorney Advertising. The law firm responsible for this advertisement is\nFaruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or\npredict a similar outcome with respect to any future matter. We welcome the\nopportunity to discuss your particular case. All communications will be\ntreated in a confidential manner.\n\nTo view the source version of this press release, please visit\nhttps://www.newsfilecorp.com/release/294678","article_body_html":"","raw_payload":{"data":{"id":"nNFC3gZcl5","title":"IBRX DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of Securities Class Action Deadline on May 26, 2026","author":"Newsfile Corp","ticker":"IBRX","created":"2026-04-28T20:48:18.274Z","tickers":["IBRX"],"exchange":"NASDAQ","article_body":"Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson\n(https://api.newsfilecorp.com/redirect/WAjqnsMp3b) Encourages Investors Who\nSuffered Losses In ImmunityBio To Contact Him Directly To Discuss Their\nOptions\n\nIf you purchased or acquired securities in ImmunityBio\n(https://api.newsfilecorp.com/redirect/qpg2EUKepK) between January 19, 2026\nand March 24, 2026 and would like to discuss your legal rights, call Faruqi &\nFaruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext.\n1310).\n\n[You may also click here for additional information]\n(https://api.newsfilecorp.com/redirect/nogWRuMqLj)\n\nNew York, New York--(Newsfile Corp. - April 28, 2026) - Faruqi & Faruqi, LLP\n(https://api.newsfilecorp.com/redirect/KL50ASJGqw), a leading national\nsecurities law firm, is investigating potential claims against ImmunityBio,\nInc. (\"ImmunityBio\" or the \"Company\") (NASDAQ: IBRX) and reminds investors of\nthe May 26, 2026 deadline to seek the role of lead plaintiff in a federal\nsecurities class action that has been filed against the Company.\n\n(https://images.newsfilecorp.com/files/6455/294678_3eff907dc4cb4ad8_001full.jpg)\n\nFaruqi & Faruqi is a leading national securities law firm with offices in New\nYork, Pennsylvania, California and Georgia. The firm has recovered hundreds of\nmillions of dollars for investors since its founding in 1995. See\nwww.faruqilaw.com.\n\nAs detailed below, the complaint alleges that the Company and its executives\nviolated federal securities laws by making false and/or misleading statements\nand/or failing to disclose that: (1) Defendant Patrick Soon-Shiong materially\noverstated Anktiva's capabilities; and (2) as a result, defendants' statements\nabout ImmunityBio's business, operations, and prospects were materially false\nand misleading and/or lacked a reasonable basis at all relevant times. When\nthe true details entered the market, the lawsuit claims that investors\nsuffered damages.\n\nOn January 23, 2026, ImmunityBio issued a press release \"announc[ing] updated\nPhase 2 clinical results from QUILT 3.078 (NCT06061809), evaluating a\nchemotherapy-free combination immunotherapy regimen in patients with\nsecond-line recurrent or progressive glioblastoma (GBM), as well as patients\ntreated under single-patient INDs (spINDs) across first- to third-line\ndisease.\" Among other results, the press release disclosed that \"median\noverall survival\"-the primary endpoint for the trial-\"has not yet been\nreached[.]\"\n\nOn this news, ImmunityBio's stock price fell $0.89 per share, or 12.13%, to\nclose at $6.45 per share on January 23, 2026.\n\nThe court-appointed lead plaintiff is the investor with the largest financial\ninterest in the relief sought by the class who is adequate and typical of\nclass members who directs and oversees the litigation on behalf of the\nputative class. Any member of the putative class may move the Court to serve\nas lead plaintiff through counsel of their choice, or may choose to do nothing\nand remain an absent class member. Your ability to share in any recovery is\nnot affected by the decision to serve as a lead plaintiff or not.\n\nFaruqi & Faruqi, LLP also encourages anyone with information regarding\nImmunityBio's conduct to contact the firm, including whistleblowers, former\nemployees, shareholders and others.\n\nTo learn more about the ImmunityBio class action, go to www.faruqilaw.com/IBRX\nor call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or\n212-983-9330 (Ext. 1310).\n\nFollow us for updates on LinkedIn\n(https://api.newsfilecorp.com/redirect/7n5B2uMyKW), on X\n(https://api.newsfilecorp.com/redirect/ejgD7UMAE7), or on Facebook\n(https://api.newsfilecorp.com/redirect/87LE2cOKvk).\n\nAttorney Advertising. The law firm responsible for this advertisement is\nFaruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or\npredict a similar outcome with respect to any future matter. We welcome the\nopportunity to discuss your particular case. All communications will be\ntreated in a confidential manner.\n\nTo view the source version of this press release, please visit\nhttps://www.newsfilecorp.com/release/294678"},"type":"article","timestamp":"2026-04-28T20:48:18.316838151Z","server_sent_at_ms":1777409298316},"received_at":"2026-04-28T20:48:18.369Z","source_url":"https://www.newsfilecorp.com/release/294678"},"analysis":{"id":"9151","press_release_id":"11816","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":["federal securities class action filed","allegations of materially overstated product capabilities"],"eventType":"legal_litigation","narrative":"Faruqi & Faruqi, LLP reminded investors of the May 26, 2026 deadline to seek lead plaintiff status in a federal class action against ImmunityBio.\n\nThe complaint alleges the company overstated Anktiva's capabilities, leading to a 12.13% stock drop on January 23, 2026.\n\nThe class period covers purchases between January 19, 2026 and March 24, 2026.","sentiment":"bearish","agentHooks":{"shouldPost":true,"suggestedAngle":"Securities fraud lawsuit alleges ImmunityBio overstated Anktiva's efficacy; class period defined."},"keyFigures":{"customDimensions":{"stock_drop_percent":"12.13%","lead_plaintiff_deadline":"May 26, 2026"}},"quotedText":"The complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements","namedEntities":{"people":[{"name":"James (Josh) Wilson","role":"Partner"},{"name":"Patrick Soon-Shiong","role":"Defendant"}],"products":["Anktiva"],"companies":[{"name":"ImmunityBio, Inc.","ticker":"IBRX"},{"name":"Faruqi & Faruqi, LLP","relationship":"Plaintiff Counsel"}],"dollarAmounts":[{"amount":"$0.89 per share","context":"stock price decline on January 23, 2026"},{"amount":"$6.45 per share","context":"closing stock price on January 23, 2026"}]},"materialImpact":{"score":3,"reasoning":"Federal securities class action alleging false statements about Anktiva's capabilities. The stock dropped 12% on Jan 23, 2026, and a lead plaintiff deadline has been set."},"tickerRelevance":{"others":[],"primary":"IBRX"},"globalImportance":35,"audienceRelevance":45,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"mid-cap","eventGravity":"class action litigation","sectorWeight":"biotech","householdBrandBoost":0}},"event_type":"legal_litigation","event_type_secondary":null,"sentiment":"bearish","material_impact_score":3,"narrative":"Faruqi & Faruqi, LLP reminded investors of the May 26, 2026 deadline to seek lead plaintiff status in a federal class action against ImmunityBio.\n\nThe complaint alleges the company overstated Anktiva's capabilities, leading to a 12.13% stock drop on January 23, 2026.\n\nThe class period covers purchases between January 19, 2026 and March 24, 2026.","key_figures":{"customDimensions":{"stock_drop_percent":"12.13%","lead_plaintiff_deadline":"May 26, 2026"}},"named_entities":{"people":[{"name":"James (Josh) Wilson","role":"Partner"},{"name":"Patrick Soon-Shiong","role":"Defendant"}],"products":["Anktiva"],"companies":[{"name":"ImmunityBio, Inc.","ticker":"IBRX"},{"name":"Faruqi & Faruqi, LLP","relationship":"Plaintiff Counsel"}],"dollarAmounts":[{"amount":"$0.89 per share","context":"stock price decline on January 23, 2026"},{"amount":"$6.45 per share","context":"closing stock price on January 23, 2026"}]},"model_name":"glm-4.7","prompt_hash":"sha256:1fc968c3ac7f7ebb","schema_hash":"sha256:1f8af1196c7db48c","created_at":"2026-04-28T23:35:23.521Z","global_importance":35,"audience_relevance":45,"importance_components":{"tickerTier":"mid-cap","eventGravity":"class action litigation","sectorWeight":"biotech","householdBrandBoost":0}},"durationMs":105947,"modelName":"glm-4.7"}}